Compare Bristol-Myers Squibb Co (BMY) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Harmony Gold Mining Co. — how do they compare? Bristol-Myers Squibb Co trades at $58.64 (market cap $116.30B), while Harmony Gold Mining Co. trades at $14.99 (market cap $9.59B). The key difference: Bristol-Myers Squibb Co is far larger — about 12.1× Harmony Gold Mining Co.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | HMY | |
|---|---|---|
Market Cap | $116.30B | $9.59B |
Sector | Health | Basic Materials |
52-Week High | $62.37 | $26.04 |
52-Week Low | $42.60 | $12.61 |
Enterprise Value | $152.24B | $9.93B |
Dividend Yield | 4.42% | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Harmony Gold Mining (HMY) trades at $14.99, down 0.79% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with 2024 revenue of $61.38 billion and net income of $8.59 billion, yielding robust profitability margins. Recent earnings were mixed, beating in Q2 2025 but missing in Q4 2025. Analyst sentiment is cautious with 70% hold ratings, while news highlights stock volatility tied to gold price sensitivity and Fed policy expectations.
HMY presents a valuation opportunity with low P/E (9.59) and EV/EBITDA (5.05) multiples, supported by high ROE (32.32%) and a 4.06% dividend yield. Key risks include gold price exposure, operational execution in its pivot to gold-copper hybrid model, and macroeconomic headwinds from potential interest rate hikes. Institutional consensus leans neutral, suggesting patience for copper project contributions to justify higher multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
